3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Cyclophosphamide
8
Flow Cytometry
6
Methylprednisolone
5
Melphalan
5
Therapeutics
4
Psychiatric Rehabilitation
4
Busulfan
4
Antilymphocyte Serum
4
Radiotherapy
3
Polymerase Chain Reaction
3
Immunologic Techniques
3
Filgrastim
3
Caspofungin
3
Amplified Fragment Length Polymorphism Analysis
3
Alemtuzumab
3
venetoclax
2
thymoglobulin
2
liposomal amphotericin B
2
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Voriconazole
2
Thiotepa
2
Thalidomide
2
Peripheral Blood Stem Cell Transplantation
2
Ondansetron
2
Nivolumab
2
Itraconazole
2
Ipilimumab
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
bempegaldesleukin
×
Other hematologic neoplasm
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts